In Massachusetts, Xenetic Biosciences, Inc. has a new Chief Scientific Officer, Curtis A. Lockshin. Lockshin’s experience with research and development in the biopharmaceutical industry and his various biomaterials, therapeutics and biosensors inventions and patents will come in handy in his new role at Xenetic, a biopharmaceutical company. Lockshin was formerly a CEO, or served in other executive roles, at SciVac Therapuetics, VBI Vaccines, Guardum Pharmaceuticals, and OPKO Health. Lockshin will help Xenetic with their focus on next-gen biologic drugs and oncology therapeutics. Scott Maguire, Chief Executive Officer of Xenetic said in their press release “With our second important executive level appointment since our Nasdaq listing, Xenetic now has a structure to deliver on what we believe will be a transformational 2017.”
Latest article
Body-based burial: Students imagine urns made from blood and hair
In Slovenia, students at University of Ljubljana have used biobased materials for a variety of design projects, including a biodegradable urn made of blood...
Uttar Pradesh eyes cow poop plastics to boost rural economy
In Uttar Pradesh, a government project is collecting cow dung to convert into usable products such as bioplastics, textiles, and paper.
The Press Trust...
Luxury brand Velvet Eyewear lauds advances in biobased acetate
In California, luxury women’s eyewear brand Velvet Eyewear has unveiled its first biobased eyewear collection.
Crafted from renewable sources like wood pulp and cotton...